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 Meet KO…
 Discussion of Treatment-Resistant Depression (TRD) 
 Discuss and share general approaches to patient 
information (based on most current evidence) 
 Discuss medication adverse effects, intolerances and safety 
implications (based on most current evidence) 
 Make a therapeutic suggestion for KO looking at the 
factors that make her a unique individual 
 Facilitate and direct Question-AND-Answer session 
 KO is a 34 year old female with a history of major 
depressive disorder (recurrent, severe). She reports 
that while she is feeling more “able to do things” she is 
not feeling any less depressed, especially in the 
evenings when she is home alone and trying to unwind. 
She denies any suicidal thoughts but reports that she 
will often just cry in front of the television. She was 
titrated to bupropion 200 mg PO daily while using 
sertraline 150 mg PO QAM. This combination has been 
used for 4 weeks. She wants to know if anything else 
can help her to manage her depression and reduce 
symptoms. 
 What would you like to know about KO? 
 Medication History 
 Treatment duration and dose optimization 
 Allergies and intolerances 
 Other medical or psychiatric conditions 
 Prior suicide attempts 
 Medication History 
◦ Past medication trials  
◦ Adherence history 
◦ Intolerances 
◦ Reasons for discontinuation 
◦ Health-belief models 
 Treatment duration and dose optimization 
◦ Time frame for gauging efficacy 
◦ Dose titration 
◦ Optimal response time 
◦ Placebo effect 
◦ “Switching” 
◦ Combinations 
 A Note on Combinations 
◦ Use of 2 antidepressants – Possible Complications 
 Drug – drug interactions 
 Serotonin syndrome 
 Neuroleptic malignant syndrome (dopamine effects with 
serotonergic effects) 
◦ Adding non-antidepressant to antidepressant 
 Buspirone
 Atomoxetine
 Lithium 
 Liothyronine
 Lamotrigine
 Atypical antipsychotics 
 Allergies 
◦ Anaphylactic reactions
◦ Generally rare with psychiatric medications 
 Intolerances 
◦ Sedation 
◦ Weight gain 
◦ Movement disorders 
◦ Anxiogenesis
◦ Sexual dysfunction 
◦ Other negative experiences 
 Other medical and psychiatric conditions 
◦ Bipolar I and II 
◦ Anxiety disorders 
◦ Insomnia and sleep disorders 
◦ Psychosis / schizophrenia 
◦ Hypertension and cardiac disease 
◦ Chronic metabolic disorders 
◦ Immune-suppression
◦ Age considerations 
 Antidepressant Medication History: FLUV, PHEN, FLUOX, 
PAROX, CITAL, ESCIT, AMIT, TRAZ and MIRT
◦ Each medication was used at least 12 weeks 
◦ Partial response to symptoms included: 
 Reduced suicidal thoughts and ideation 
 Increased energy 
 Improved sleep patterns 
 Improved appetite patterns  
◦ Nagging feelings of guilt, anhedonia, and inner rumination 
persist 
 Treatment duration / Dose optimization 
◦ All titrated until target dose or side effect 
 All medications were used at therapeutic doses 
 Judicious titration methods 
 Constant follow-up 
 Adherent to appointments and treatment regimens 
 Allergies/Intolerances 
◦ No Allergies 
◦ Sexual dysfunction with FLUV, FLUOX, PAROX, CITAL, 
ESCIT
◦ Palpitations with AMIT
◦ Weight gain with TRAZ and MIRT
 Other Medical/Psychiatric Conditions and Stress Factors 
◦ Hypertension – most recent 148/94 mm Hg and 88 beats/minute  
◦ Insomnia – difficulty getting to sleep 
◦ Anxiety – general and secondary to lack of sleep – worries about losing job 
◦ Body dysmorphic disorder – worries about appearance and cosmetic 
impact of drug therapy (history of bulimia and anorexia – currently not 
vomiting or starving) 
◦ Recurring stressors: twin sister died in car accident (she was the driver 
and both had been drinking) and her work schedule did not allow her to 
attend the funeral 
◦ Currently “successful” – but cannot bring herself to enjoy anything since 
the event
 Current Medication Regimen: 
◦ Lisinopril 20 mg PO BID 
◦ Amlodipine 10 mg PO daily 
◦ ASA (OTC) 81 mg PO daily 
◦ Alli (OTC) 1-2 capsules before each fattening meal 
◦ Sertraline 150 mg PO QAM 
◦ Bupropion 200 mg PO QAM 
◦ Diphenhydramine 50 mg PO QHS as needed
 Prior overdose with OTC medications (ASA, APAP) 
and BENZOS 
◦ She has access to OTC medications such as ASA, 
Ibuprofen, APAP and antihistamines 
◦ She has no chronic problems with pain but has ASA on a 
daily basis 
◦ Takes Ibuprofen and/or APAP for pain related to exercise 
episodes (current form of “purging” calories)  
 Patient currently on optimal target doses: already using 
combination of SSRI and dopamine reuptake inhibitor 
 Combinations to avoid: 
◦ VENLA + SSRI / MIRT (bleeding) 
◦ VENLA + FLUOX (serotonin syndrome risk) 
 Options to “add-on”: 
◦ Buspirone
◦ Already on bupropion
◦ Aripiprazole, Risperidone, Ziprasidone, Quetiapine
(immediate/extended release) 
◦ Comeback of Symbyax? 
◦ Lamotrigine, liothyronine / levothyroxine
◦ Others: modafanil, atomoxetine, and methylphenidate 
 Plan A: Add nothing after determining that she 
needs to continue this combination at least 
another 4 weeks?
 Plan B: Increase the dose of either the sertraline or 
the bupropion?
 Plan C: Recommend psychotherapy or ECT when 
added to the current regimen?
 Plan D? 
 If selecting Plan A, what if it is now 2 months later 
and her problems persist? 
◦ Stopping current regimen? 
◦ Buspirone? 
◦ Lithium? Lamotrigine?  
◦ Liothyronine / levothyroxine? 
◦ Antipyschotic? 
◦ Stimulant? 
 If selecting Plan B, which medication increase 
would most benefit KO? 
◦ Sertraline? 
 Current dose 
 Maximum dose 
 Exceeding maximum dose 
◦ Bupropion? 
 Current and maximum dose 
 Adherence issues and pill burden 
 New formulations! 
 If Plan C, what are the treatment implications? 
◦ Psychotherapy for the busy professional 
 Schedule 
 Type of therapy 
 Personality 
◦ The role of ECT in treatment resistant depression 
 Medication usage 
 Chronic use of ECT 
 Complications 
Medication added to 
antidepressant
Implications on safety and monitoring for KO
Buspirone May help with anxiety 
 May cause DDI 
Lamotrigine May help with mood stability 
 Slow titration 
Lithium May help with mood stability 
 Chronic side effects and reactions / monitoring 
Thyroid therapy Different mechanism (norepinephrine addition) 
 Monitoring and Cardiovascular effects 
Antipsychotic Atypicals may provide some benefit for SX 
Chronic cardio-metabolic disorders and 
monitoring
Stimulant therapy May help with target SX 
 May cause DDI / Increase agitation or insomnia 
 Time for questions! 
 It has been my pleasure to be here with you. 
 Thank you! 
